Clinical Trials
- Child Development & Autism
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
- Ages15 years - 45 years
- GenderBoth
- Date11/22/2021
- Liver
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
- Ages18 years and older
- GenderBoth
- Date09/18/2017
- Lung Cancer
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy
- Date01/14/2022
- Digestive System, Endocrine System
A Dose Ranging Study Evaluating Efficacy and Safety of NI-03
- Ages18 years - 85 years
- GenderBoth
- Date03/01/2020
- Colorectal Cancer
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
- Date01/12/2022
- Gynecological Cancers
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
- Ages18 years and older
- GenderFemale only
- Date03/24/2021
- Phase 1 Cancers
A Multicenter, Non-randomized, Open-label Phase 1b Study to Determine the Maximum Tolerated and Recommended Phase 2 Dose of the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients With Advanced Solid Tumors
- Date01/25/2022
- Kidney Cancer
A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients With Known or Suspected Focal Liver Lesions and Severe Renal Impairment
- Ages18 years and older
- GenderBoth
- Date01/31/2020
- Kidney Cancer
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
- Date11/11/2020
- Gynecological Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
- GenderFemale only
- Date12/21/2021